Krystal Biotech

KRYS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

KRYS · Last close · October 26, 2026

$313.66

Krystal Biotech's revenue rose 33.9% to $389 million in fiscal 2025. Its operating margin was 41.5%, up from 22.6% a year earlier. Free cash flow was $189 million, up 58.5%. The diluted share count rose 0.7%.

Krystal Biotech, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 17, 2026 · 0001711279-26-000016 Updated October 16, 2026

Revenue

$389M

33.9%

Operating margin

41.5%

18.8 pts

Net income

$205M

129.7%

Free cash flow

$189M

58.5%

Return on capital

43.6%

22.9 pts

Market cap

$9.6B

Oct 26 close

P/E

39.3x

On $7.98 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Krystal Biotech has had no borrowings since its 2017 listing (its balance sheets have no debt line), so debt is zero from 2017.

Charts show fiscal years, from the 10-K filings.

Revenue and margins

Revenue

US$ billions, fiscal years

Margins

Percent of revenue

GrossOperatingNetFree cash flow

Net income and earnings per share

From fiscal 2023 to 2025, earnings per share grew 318.8% a year and net income 333.5% a year, as new shares raised the share count by 8% and diluted each share's earnings.

Net income

US$ billions, fiscal years; loss years in red.

Diluted earnings per share

US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity

Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.

Return on capitalReturn on equity

Cash flow

Free cash flow

US$ billions. Cash from operations minus capital expenditure; negative years in red.

Payouts and share count

Dividends and buybacks

US$ billions, cash paid in each fiscal year

DividendsShare buybacks

Diluted share count

Weighted-average diluted shares, millions

Valuation

Two ways to value Krystal Biotech yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.

Discounted cash flow (DCF)

A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Krystal Biotech's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.

Value per share on three example scenarios, from Krystal Biotech's cash from operations minus depreciation in fiscal 2025 (free cash flow before spending to grow: capital spending was 2.1 times depreciation, which holds its free cash flow down) of $195M, net cash of $828M at December 31, 2025 and 30 million diluted shares, from its filings. The scenarios are fitted to Krystal Biotech: the base scenario's growth in years 1 to 5 is its revenue growth over the last 2 years, 177.0% a year, kept between 0% and 20%; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 13%: 11% for a cyclical or higher-risk business (Biotechnology), plus 1 point as a smaller company, worth $9.6B, plus 1 point for unsteady results (a loss in fiscal 2022); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

From the filings

Starting free cash flow, US$ millions

Cash from operations minus depreciation in fiscal 2025: a rough guide to cash flow before spending to grow, for a company building heavily.

Net cash, US$ millions

Cash and short-term investments minus debt and finance leases at December 31, 2025. Negative means net debt.

Diluted shares, millions

Weighted-average diluted shares in fiscal 2025.

Your assumptions

Start from

Fitted to Krystal Biotech's own revenue growth, as above. Cautious: growth of 10% then 6% a year, 2% after year 10, a 14% discount rate. Base: growth of 20% then 11% a year, 2.5% after year 10, a 13% discount rate. Optimistic: growth of 25% then 14% a year, 3% after year 10, a 12% discount rate.

Free cash flow growth, years 1 to 5 (% a year)

Free cash flow growth, years 6 to 10 (% a year)

Growth after year 10 (% a year)Long-run growth forever after year 10. Usually close to inflation, and always below the discount rate.

Discount rate (% a year)The yearly return an investor wants for the risk. A higher rate gives a lower value.

Value per share on these assumptions

—

Last close, October 26, 2026: $313.66
Value on these assumptions, against the last close: —

Cash flows in years 1 to 10, valued today: —
Everything after year 10, valued today: —
Plus net cash: —
Share of value from after year 10: —

Projected free cash flow

US$ billions. Each column is one year's projected free cash flow, split into what it is worth today and the part removed by discounting.

Value todayRemoved by discounting

How the value changes with two assumptions

Value per share in US$, with the growth rates above. The highlighted cell matches the current assumptions.

How the model works. Free cash flow grows at the first rate for five years and the second rate for five more, and each year is discounted at the discount rate. Everything after year 10 is valued as year-10 cash flow × (1 + growth after year 10) ÷ (discount rate − growth after year 10), discounted back ten years. Net cash is added and the total is divided by diluted shares. The result depends entirely on the assumptions. It is not a forecast, a price target or a recommendation. The last close is the consolidated US closing price, from Databento.

Price-to-earnings (P/E) method

Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.

Value per share on three example scenarios, from Krystal Biotech's earnings per share of $7.98 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 27.8×, the middle of Krystal Biotech's own P/E today, its peers' median and its sector's median (the Health Care median) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 14%, 13% and 12%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.

Earnings per share, US$

Diluted earnings per share over the four quarters to June 30, 2026, from the 10-Qs and 10-K.

P/E multiple

P/E today is the last close divided by the latest earnings per share, the four quarters' where available. Peers: ADMA Biologics, Ligand Pharmaceuticals.

Earnings growth in the years ahead (% a year) Starts at Krystal Biotech's revenue growth over the last 2 years, 177.0% a year, kept between 0% and 20%, as the base scenario does.

Earnings per share in the years ahead, US$

Year 1Year 2Year 3Year 4Year 5

Type your own estimate for any year; the years after it carry on at the growth rate.

Apply the multiple to earnings

A multiple on a future year's earnings gives the price then, brought back to today at the discount rate below.

Discount rate (% a year) The yearly return an investor wants for the risk, as in the cash flow model.

Value per share today at this multiple

—

Last close, October 26, 2026: $313.66
Value at this multiple, against the last close: —
Krystal Biotech's P/E at the last close: 39.3×

Company	Last close	Earnings per share	P/E today
Krystal BiotechKRYS	$313.66	$7.98	39.3×
Ligand PharmaceuticalsLGND	$308.30	$9.41	32.8×
ADMA BiologicsADMA	$11.06	$0.70	15.8×

How the P/E method works. Value per share is earnings per share times the multiple. On a future year's earnings, that gives the price in that year, which is brought back to today at the discount rate: price ÷ (1 + discount rate) for each year ahead. It is quick and easy to compare across companies, but it ignores debt and cash, and earnings can swing with one-off gains and charges, so a multiple says most about steady, profitable businesses. Like the cash flow model, the result depends entirely on the assumptions you choose. It is not a forecast, a price target or a recommendation.

Balance sheet

Fiscal year end	FY21	FY22	FY23	FY24	FY25
Cash and short-term investments	438	379	532	598	828
Debt incl. finance leases	0	0	0	0	0
Net debt (negative means net cash)	−438	−379	−532	−598	−828
Net debt to EBITDA	—	—	—	−8.3x	−5.0x
Debt to equity	0.0x	0.0x	0.0x	0.0x	0.0x
Interest coverage	−45.8x	—	—	—	—
Current ratio	17.2x	13.3x	17.8x	7.3x	9.9x
Quick ratio	17.2x	13.3x	17.6x	7.0x	9.6x

US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Insider trades

Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Krystal Biotech shares on the open market, and 6 insiders sold $105.3 million, $92.1 million of it under trading plans set up in advance.

Date	Insider	Trade	Shares	Price	Value	Filing
Sep 4, 2026	Krish S KrishnanPresident and CEO, Director, 10% owner	Sold plan	25,000	$359.32	$9.0 million	Form 4
Sep 4, 2026	Suma KrishnanPresident, R&D, Director, 10% owner	Sold plan	25,000	$359.32	$9.0 million	Form 4
Aug 14, 2026	Dino A RossiDirector	Sold	25,000	$329.12	$8.2 million	Form 4
Jun 25, 2026	John Charles ThomasEVP, General Counsel	Sold plan	1,000	$347.27	$347,270	Form 4
Jun 4, 2026	Krish S KrishnanPresident and CEO, Director, 10% owner	Sold plan	25,000	$308.12	$7.7 million	Form 4
Jun 4, 2026	Suma KrishnanPresident, R&D, Director, 10% owner	Sold plan	25,000	$308.12	$7.7 million	Form 4
May 26, 2026	John Charles ThomasEVP, General Counsel	Sold plan	642	$302.03	$193,903	Form 4
Mar 4, 2026	Suma KrishnanPresident, R&D, Director, 10% owner	Sold plan	25,000	$263.21	$6.6 million	Form 4
Mar 4, 2026	Krish S KrishnanPresident and CEO, Director, 10% owner	Sold plan	25,000	$263.17	$6.6 million	Form 4
Mar 2, 2026	Kathryn RomanoChief Accounting Officer	Sold plan	750	$267.60	$200,700	Form 4
Feb 27, 2026	Daniel JanneyDirector	Sold plan	11,803	$275.59	$3.3 million	Form 4
Feb 26, 2026	Daniel JanneyDirector	Sold plan	7,741	$275.63	$2.1 million	Form 4

The latest 12 of 18 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Piotroski F-score

The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.

Test	FY23	FY24	FY25
Net income is positive	Pass	Pass	Pass
Cash from operations is positive	Fail	Pass	Pass
Return on assets rose	Pass	Pass	Pass
Cash from operations exceeds net income	Fail	Pass	Fail
Debt fell relative to assets	Fail	Fail	Fail
Current ratio rose	Pass	Fail	Pass
Share count didn't rise	Fail	Fail	Fail
Gross margin rose	—	—	—
Revenue rose relative to assets	Pass	Pass	Pass
F-score	4 of 8	5 of 8	5 of 8
Accruals ratio	14.5%	−3.7%	0.3%

The accruals ratio is net income minus cash from operations, over average total assets.

Compare

Put Krystal Biotech side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

Company	Year	Revenue growth	Operating margin	Free cash flow margin	Return on capital	Net debt to EBITDA	F-score	Compare
Krystal Biotech	FY25	33.9%	41.5%	48.5%	43.6%	−5.0x	5
ADMA Biologics	FY25	19.6%	37.5%	5.5%	39.5%	−0.1x	5	Compare
Ligand Pharmaceuticals	FY25	60.4%	15.3%	18.2%	4.9%	−3.8x	5	Compare
Repligen	FY25	16.4%	7.5%	12.7%	2.4%	−1.7x	—	Compare
Arrowhead Pharmaceuticals	FY25	23,258.2%	11.9%	18.9%	—	−5.5x	5	Compare

Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score above.

10 years of figures

Fiscal year	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Income statement
Revenue	—	—	—	—	—	0	0	51	290	389
Revenue growth	—	—	—	—	—	—	—	—	473.0%	33.9%
Gross profit	—	—	—	—	—	—	—	—	—	—
Research and development	1	3	8	16	18	28	42	46	54	58
Operating income	−1	−5	−12	−22	−33	−68	−145	−110	66	161
Net income	−1	−8	−11	−19	−32	−70	−140	11	89	205
Diluted EPS (US$)	−1.31	−1.48	−0.97	−1.20	−1.71	−3.13	−5.49	0.39	3.00	6.84
Diluted shares (millions)	1	5	11	16	19	22	26	28	30	30
Cash flow
Cash from operations	−1	−4	−9	−19	−26	−48	−101	−89	123	201
Capital expenditure	0	0	2	6	15	68	53	12	4	12
Free cash flow	−1	−4	−12	−25	−41	−116	−154	−101	119	189
Dividends paid	0	0	0	0	0	0	0	0	0	0
Share buybacks	0	0	0	0	0	0	0	0	0	0
Acquisitions	0	0	0	0	0	0	0	0	0	0
Stock-based compensation	0	0	1	1	3	15	33	40	49	54
Balance sheet at fiscal year end
Cash and short-term investments	2	50	112	194	271	438	379	532	598	828
Debt incl. finance leases	1	0	0	0	0	0	0	0	0	0
Total assets	2	50	116	209	311	626	558	818	1,056	1,334
Total liabilities	2	1	3	6	19	33	36	40	110	114
Shareholders' equity	0	50	113	203	292	594	522	779	946	1,220
Margins and ratios
Gross margin	—	—	—	—	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—	—	−216.2%	22.6%	41.5%
Net margin	—	—	—	—	—	—	—	21.6%	30.7%	52.6%
Free cash flow margin	—	—	—	—	—	—	—	−198.4%	41.0%	48.5%
Return on capital	—	—	—	—	—	−61.2%	−76.8%	−47.7%	20.6%	43.6%
Return on equity	—	−31.8%	−13.4%	−12.1%	−13.0%	−15.7%	−25.1%	1.7%	10.3%	18.9%
Return on assets	—	−30.3%	−13.1%	−11.7%	−12.4%	−14.8%	−23.6%	1.6%	9.5%	17.1%
Net debt to EBITDA	—	—	—	—	—	—	—	—	−8.3x	−5.0x

US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)

Source: Krystal Biotech's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Krystal Biotech.